Article Per Year (5 Year)
p-Index From 2021 - 2026
0.23
P-Index
This Author published in this journals
All Journal MEDICINUS
Andika Yusuf Ramadhan
Clinical Pharmacology Specialist Study Program, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia and Genetic Counseling Concentration, Master of Biomedical Sciences Program, Faculty of Medicine, Universitas Yarsi, Jakarta, Indonesia
Biochemistry, Genetics & Molecular Biology Immunology & microbiology Medicine & Pharmacology Neuroscience Public Health

Published : 1 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 1 Documents
Search

 1 
Pharmacogenomics and Precision Pharmacotherapy in Heart Failure: A Narrative Review Andika Yusuf Ramadhan
MEDICINUS Vol. 39 No. 8 (2026): MEDICINUS
Publisher : PT Dexa Medica

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.56951/51m6s534

Abstract

Heart failure is a life-threatening condition affecting approximately 1% of the global population, with its prevalence continuing to rise. Genetic factors, including pathogenic variants in sarcomere, cytoskeletal, and ion channel genes, contribute to disease progression, often following Mendelian inheritance patterns. However, most interindividual variability in disease course and therapeutic response arises from polygenic, non Mendelian patterns, particularly single nucleotide polymorphisms (SNPs). SNPs can modestly influence gene expression, protein function, and downstream signaling pathways, thereby affecting the pharmacokinetics and pharmacodynamics of cardiovascular drugs. Variants in genes such as CYP2D6, ACE, AGT, CYP11B2, ADRB1/2, SLC5A2, and UGT2B4 have been associated with differential responses to β-blockers, SGLT2-inhibitors, and ACE inhibitors. The clinical application of genomic approaches remains limited due to small study sizes, interpatient variability, and the lack of standardized biomarkers. Nevertheless, integrating genetic, epigenetic, and phenotypic data offers a promising strategy to guide more effective and individualized heart failure pharmacotherapy.
Co-Authors